The opiate-antagonist naloxone has been used successfully to reverse non-opiate induced respiratory, cardiovascular, and central nervous depression. This has included reversal of diazepaminduced respiratory depression j and diazepamrelated central nervous system depression in man. ~ Reversal by naloxone of experimental endotoxic, electro-convulsive, and hypovolemic shock in the rat has been demonstrated, 3-5 while an increase in the LDs0 of pentobarital in the rat was postulated to be another beneficial effect of the antagonist. 6 Additionally, naloxone had been reported to be a useful drug in the treatment of severe catatonic schizophrenia and of ethanol intoxication. 7 In patients comatose due to the combined effect of barbiturates, alcohol and diazepam, naloxone reversed the non-opiate induced apnea, a Antagonization of endogenous opioids (enkephalins or endorphins) at opiate binding sites in the CNS is proposed as the mechanism of action of naloxone. Others, however, question the secondary release of endogenous opioids by non-opiate anaesthetics and sedatives. They were unable to demonstrate any beneficial effect of naloxone administration in diazepam-sedation, 9 thiopental anaesthesia in man t~ and in the pentobarbital anaesthesia in mice. 11 Similarly, there have been conflicting reports on the effect of naloxone in reversing halothane and/or nitrous-oxide anaesthesia. The original positive results of Finck and Berkowitz in the rat] 2 later corroborated by Yang et el. in man t3 have not been confirmed by other laboratories. [14] [15] [16] [17] [18] [19] Since we had previously demonstrated that cerebro-ventricular perfusion of naloxone reversed the CAN ANAESTH SOC J 1983 / 30:3 i pp235-241 hypnotic effect and depressed baroreceptor reflex activity during halothane anaesthesia, 18 the following study was undertaken in order to evaluate whether intravenous naloxone is able to induce similar antagonistic effects. Three questions were of particular interest. 1 Is naloxone able to reverse halothane-induced hypnosis and the depressed carotid sinus reflex? 2 At what time after the injection does naloxone reverse the halothane-depressed carotid sinus reflex? 3 What is the most effective dose of the nntagonist?
Materials and Methods
Six dogs chronically prepared for repetitive arterial blood pressure measurement in the awake state were used for the experiments. Mean arterial blood pressure was measured via a Statham P 32 wansducer through one of the previously exteriorized carotid loop arteries, 2~ and heart rate was derived from the ECG (lead II) by means of a cardiotachometer-coupler (Mingograph, SiemensElema). By clamping both exteriorized common carotid arteries, carotid-sinus mediated reflex effects on blood pressure and heart rate were evaluated. EEG activity of the frontal region was detected by electrodes which were plastered to the animal's scalp rasing colloidon in position CytC4 . The indifferent electrode was placed on the dog's nasal bone. 21 The neuronal activity was amplified by a Schwarzer EEG recorder (time constant 0.3 s and cut off frequency at 30 Hz) and recorded on chart as well as on magnetic tape (Philipps Analog 7). The recordings on the magnetic tape were later used for computerized power spectral analysis (Plurimat-S).
Representative examples of power spectra of the frontal cortical activity dtmng wakefulness were used for the evaluation of the state of consciousness during the halothane anaesthesia, as well as during the time course of different doses of naloxone (100 and 200 ~g'kg-l).
Analysis of the EEG
Power spectral analysis of the EEG was performed with a digital computer based signal analyser (Plurimat-S) from artefact-free 200 s recordings after signal conditioning with an active bandpass filter (Krohn Hite Model 33 43, Butterworth type with a frequency band between 0.25 to 30 Hz).
The spectra were used to determine the state of wakefulness. The computer was programmed to divide the EEG spectrum into various frequency bands:
12.50 -20.00 Hz = beta-band (awake) 8.00-12.50 Hz = alpha-band (drowsiness) 4.10 -8.00 Hz = theta-band (light sleep) 0.25 -4.10 Hz = delta-band (deep sleep)
The mean power spectra were averaged from 10 epochs (each with a duration of 20 sec), and the results displayed on a Tektronix R 4010 display terminal and copied by a Tektronix R 4631 hard copy unit. Logarithmic scaling was chosen for a reasonable representation of both the power (yaxis) and frequency (x-axis).
Power spectrum or energy spectrum determines the amplitude2/frequency, i.e. the energy contained in a wave per entity or bandwidth (MV2).
Experimental protocol
After control measurements during the awake state, anaesthesia was induced with methohexital (5 mg. kg -I i.v.). The animals were then intubated and attached to an anaesthesia machine (Drager Romulus), breathing spontaneously while anaesthesia was maintained with halothane using a calibrated vapourizer (Dr~ger Vapor) at a concen~ation starting with 1.5 Vo1%/O2. This concentration was gradually reduced until a constant end-tidal halothane concentration was reached which just left the animals unconscious and unresponsive to painful stimuli such as nose clamping. Generally, a concentration of about 0.65 Vol% halothane in oxygen was required, as measured by a gas analyser (Engstrrm Multigas Monitor). Mean arterial blood pressure, heart rate and EEG frontal activity were continuously recorded on a Mingograph recorder (Siemens-Elema).
After 60 minutes, end-expiratory halothane coneentration remained stable, suggesting equilibration of alveolar and brain anaesthetic concentrations. During this time, both common carotid arteries were clamped on three occasions. Naloxone was then given intravenously in a bolus injection of 100 I.Lg'kg -j .
Both common carotid arteries were clamped for one minute in order to evaluate carotid sinus reflex activity, as reflected in the amoun! of the increase in blood pressure and heart rate at 5, 10, 15, 20, 25 and 30 rain after naloxone injection.
On the following day, the same animal was 
Statistical Evaluation
Data obtained during pure halothane anaesthesia were compared to data for the 5, 10, 15, and 20 minute points following naloxone injection, using the two-tailed test of Wilcoxon-Rank. Statistical significance was considered as p ~ 0.05.
Results
The EEG power spectral analysis, reflecting the state of consciousness, shows that con~ary to the awake, control state with a dominant power in the beta-band (15-30 Hz), halothane anaesthesia induced a shift of power maxima to the lower frequency band, ranging from theta to delta (0.5-8 Hz), the latter resembling a state of unconsciousness and hypnosis. This change is demonstrated in a representative example (Fig. 1) where the additional administration of naloxone 100 ~g.kg -I during halothane (0.64 VoI% in pure oxygen) induces only a small increase in power in the higher frequency band around 20 Hz. A dose of 200 ~g.kg -1, however, gradually induces a reduction of power maxima of the delta-band (0.25-4 Hz), which finally results in a shift of power from the low to the higher frequency band (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) in the 20th rain post injection.
The percentage change in power of the various frequency bands of six experiments during halothane anaesthesia and after (20') naloxone injection is summarized in Table 1 . It can be seen that in the delta (0.5-3.5 Hz) and alpha-band (7.5-13 Hz) there is a significant decrease of power (p < 0.05) while in the higher frequency bands (18-25; 25-30 Hz) only beta4 (25-30 Hz) demonstrates a significant increase (p = 0.05). These changes in cortical activity can be labelled as arousal.
These time dependent changes in EEG activity are demonstrated in another representative example (Fig. 2) showing the amplified neuronal activity of the frontal cortex as they are originally recorded. From the awake state with high frequency, low amplitude waves, cortical activity changes into low frequency, high amplitude waves when halothane has been administered for 60 rain. Naloxone injee- Halothane induces a marked increase of power in the delta-and theta-bands; subsequent naloxonr injection (200 ~g-kg -~) induces a reduction in delta, theta ~d a~pha and art met'ease of Iotat power in the beta-bated. The t-test for paired observations (halothane-ndoxonc) is significant in delta, alpha, and beta, indicating "arousal." Holothone ~lus N~toxone 02mgtkg 35rain FIGURE 2 Repres~tative example of EEG activity during the awake state, during halothane anaesthesia, m~d during different time intervals after naloxone 0.2 mg.kg-1 injection. NOT~: low frequency, high amplitude waves, characteristic for the anaesthetic state are gradually reversed by naloxone to high frequency, low amplitude waves, the latter representing a picture similar to the awake state. This effect is pronounced around the 20th to 25th min post injection. Thereafter the arousal effect wears off and at the 35th minute a pattern similar to the halothaue anaesthetic state is again dominant.
tion in a bolus of 200 p,g'kg -t gradually reverses this pattern, inducing EEG activity which is similar to the awake control state, ~t about 20 to 25 minutes following injection. Thereafter the naloxone effect wears off, and a pattern with low frequency, high amplitude waves, similar to pure halothane anaesthesia, becomes dominant. The time dependent changes in EEG activity coincide with a change in the animals' behaviour: From a state of unresponsiveness to noxious stimuli, i.e. nose clampling, naloxone injection induced hyperventilation, moving and stiffening of the head until finally the animals opened their eyes while some of them reacted to the tracheal tube.
Compared to the control conscious state, halothane induced characteristic cardiovascular changes: bradycardia, hypotension, and depression of the baroreceptor reflex. These changes were gradually reversed by naloxone 200 la, g.kg -t i.v., as demonslrated in Fig. 3 . At about 15 to 20 minutes after injection of the naloxone there was a significant increase in baroreceptor activity when compared to halothane anaesthesia alone. This effect is so pronounced that control values of the conscious state are reached. Thereafter the increased reflex activity shows a gradual decline to the halothane anaesthesia levels.
While naloxone was able to reverse the halothaneinduoed depression of the carotid sinus reflex, there was no such effect on the anaesthesia-induced hypotension and bradycardia.
Discussion
These results demonstrate that naloxone is able to reverse halothane-induced depressed baroreflex activity and hypnosis, but not the anaesthesiarelated hypotension and bradycardia. The exact site of action of naloxone cannot be distinguished from the present study. The antagonist might for example exert a direct effect on the sensitivity of the carotid sinus stretch receptors. It might, however, also have a direct effect on the vasomotor centers within the brain-stem which supply the efferent output. Previous experiments using the selective perfusion technique in the halothane anaesthetized dog, indicate that the naloxone arousal reaction is initiated from a structure bordering the fourth cerebral ventricle, ts Since stereospecificity was demonstrated, opiate binding sites were postulated as a class of putative receptors interacting with halothane-released endogenous opiate-like peptides. These earlier findings and the EEG changes seen following naloxone indicate a central effect of the antagonist. The present results show that in contrast to the well-established competitive antagonism of opiate effects by naloxone within two to five minutes, initiation of an arousal reaction during halothane anaesthesia only developed fully 20 minutes following injection. This long latency suggests that a direct interaction with the opiate receptors is unlikely.
If naloxone displaces endogenous opioids competitively from opiate receptors, a great deal less naloxone than 200 i.~g.kg -t should have been required for total opiate receptor occupation in the CNS. For instance, only 5 lxg.kg -l of naloxone is necessary to reverse the respiratory, circulatory and EEG effects of 210 izg-kg -1 of morphine within two to four minutes 22 when the brain concentration of naloxone is expected to be high. z3 These differences in the dose requirements and time courses of the antagonistic effect in opiate anaesthesia and the initiation of an "arousal" reaction during halothane anaesthesia imply that the receptors involved in the centrally mediated analeptic reaction may have unique properties, distinct from specific opiate binding sites, Such a non-antagonistic but analeptic effect of naloxone on the state of consciousness in patients after anaesthesia has been considered by Aldrete and Goldman. 24 Similarly Chapman and Benedetti 25 demonstrated a non-specific and partial reversal of the central depressive effect of nitrous oxide on cerebral evoked potentials in man and Artu et al. 26 noted a naloxone-induced rise in EEG frequency with a concomitant fall in amplitude, in the halothane anaesthetized dog, as in the present study. Non-specific EEG arousal reactions of the antagonist are reported by Roy and Stullken 27 where naloxone as well as doxapram and physiostigmine were able to reverse EEG effects of sub-MAC halothane.
Last but not least, the selectivity of naloxone for opiate binding sites has been questioned because of evidence that the compound also blocks gammaaminobutyric acid (GABA), a transmitter which inherits inhibitory properties in the CNS. 2s
Why, however, did other researchers fail to detect any effect of naloxone on halothane anaesthesia? In these studies 14'15'19 naloxone in high to massive doses (2000-2500 ttg.kg -l) did not reverse nitrous-oxide-or halothane-induced depression of the writhing response in the rat. First is the notion that a massive dose of the essentially "pure" antagonist naloxone may unmask morphinomimetic properties such as miosis and sedation reactions which have been observed in the dog. ~9 Second is the concept that naloxone binds preferentially to the Ix-type opiate receptor, 3~ a subunit of opiate binding sites as originally described by Martin et al. 31 Opioid peptides correspond more to the deltareceptor, 32 another subpopulation of opiate receptors with which selective Ix-agonists (e.g. morphine or fentanyl) or a ix-selective antagonist (e.g. naloxone) show less affinity. 3a If halothane really does induce the release of endogenous opioid peptides (enkephalins or endorphines), then naloxone can be considered as a poor delta-receptor antagonist. 32,33 Other more specific antagonists might be more useful in reversing halothane-induced changes.
Thirdly, there is suspicion that different strains of animals may possess different subpopulations of opiate-receptors, binding sites which demotlstrate reduced interaction with the opiate antagonist naloxone. Such a view is reinforced by experiments where naloxone was unable to change the nociceptire threshold in normotensive rats, but induced a decreased nociceptive threshold in spontaneously hypertensive rats. 34 This study has demonstrated a possible favourable role of the antagonist naloxone on emergence from halothane anaesthesia. Such a beneficial effect may only be obvious when low concentrations of halothane are present, as in the immediate postanaesthetic period. Naloxone may then lead to a more rapid normalisation of halothane depressed blood pressure and heart rate iegulating reflexes and of reduced consciousness. However, it remains to be determined what dose regimen is necessary to elicit similar effects in man.
